Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors?

Clin Imaging. Jul-Aug 2012;36(4):360-4. doi: 10.1016/j.clinimag.2011.11.005. Epub 2012 Jun 8.

Abstract

Material and methods: Within the group of 47 patients treated with peptide receptor radionuclide therapy (PRRT), four patients were chosen: three with inoperable tumors without liver metastases and one with two lesions in the pancreas and metastases.

Results: In all patients, after PRRT, the changes in the sum of the longest diameters of tumors were between -1% and -21%, resulting in stable disease reported [strict Response Evaluation Criteria in Solid Tumors (RECIST)]. But the measurements of tumor volume and attenuation in computed tomography and the tumor to nontumor ratio in somatostatin receptor scintigraphy resulted in different response assessments.

Conclusions: The RECIST standard may be not sufficient to properly assess the therapy response in patients with neuroendocrine tumors.

MeSH terms

  • Aged
  • Brachytherapy / methods*
  • Female
  • Follow-Up Studies
  • Humans
  • Liver Neoplasms / secondary
  • Male
  • Middle Aged
  • Molecular Targeted Therapy
  • Neoplasm Invasiveness / pathology
  • Neoplasm Staging
  • Neuroendocrine Tumors / diagnostic imaging
  • Neuroendocrine Tumors / pathology*
  • Neuroendocrine Tumors / radiotherapy*
  • Outcome Assessment, Health Care / methods*
  • Outcome Assessment, Health Care / standards*
  • Prognosis
  • Radioisotopes / therapeutic use
  • Radiopharmaceuticals / therapeutic use
  • Receptors, Peptide / therapeutic use*
  • Risk Assessment
  • Tomography, Spiral Computed / methods*
  • Treatment Outcome
  • Tumor Burden

Substances

  • Radioisotopes
  • Radiopharmaceuticals
  • Receptors, Peptide